Twist Bioscience Corp vs Vistra Corp — how do they compare? Twist Bioscience Corp trades at $163.25 (market cap $10.08B), while Vistra Corp trades at $159.21 (market cap $52.41B). The key difference: Vistra Corp is far larger — about 5.2× Twist Bioscience Corp's market cap, and Vistra Corp pays a 0.59% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Vistra Corp for 32 Days on average.
| TWST | VST | |
|---|---|---|
Market Cap | $10.08B | $52.41B |
Volume | 4,229,037 | 11,278,074 |
Sector | Health | Utilities |
52-Week High | $205.00 | $210.85 |
52-Week Low | $25.45 | $134.71 |
Typical Hold Time | 27 Days | 32 Days |
Enterprise Value | $10.01B | $74.34B |
Dividend Yield | — | 0.59% |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% over 24 hours, with a bearish technical signal and negative cash flows. Revenue growth is strong, reaching $377M in 2025, but the company remains unprofitable with a net income margin of -31.66%. Recent news highlights its role in Eli Lilly's AI-driven drug discovery platform, boosting sentiment despite earnings misses.
The outlook is mixed: analyst consensus is bullish with a $145.20 price target, but high valuation multiples and persistent losses pose risks. Investment opportunity hinges on AI partnerships driving future profitability, while execution risks and cash burn require careful monitoring.
Vistra Corp (VST) trades at $156.19, down 6.32% today, but maintains strong analyst support with 91% buy ratings and a $215.23 consensus target. The stock shows bullish technical signals with support at $152 and resistance at $164, while fundamentals reveal impressive 75.73% ROE and 11.55% net margin. Recent developments include a $4.2 billion US loan for nuclear expansion and a 20-year power deal with New Era Energy, positioning Vistra to capitalize on AI-driven electricity demand.
Vistra presents compelling growth potential as a key beneficiary of AI infrastructure expansion, with strong profitability metrics and institutional backing. However, investors face risks from volatile earnings performance (two recent EPS misses) and execution challenges in capital-intensive energy projects. The stock's current discount to analyst targets offers upside potential if the company can consistently deliver on its nuclear expansion and data center power contracts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →